Biocircuits to ship IOS point-of-care immunodiagnostic system in early 1996.
This article was originally published in The Gray Sheet
Executive Summary
BIOCIRCUITS' IOS POINT-OF-CARE IMMUNODIAGNOSTIC SYSTEM SHIPMENTS are expected to begin in early 1996, the company says. Cleared for marketing by FDA on Dec. 1, the physician-office/point-of-care instrument is being sold for $6,000. The intended market for the device is the approximately 45,000 small- to medium-sized physician practices that already do clinical chemistry and/or hematology testing in-house but use outside labs for immunodiagnostic testing.